Top of this page
Skip navigation, go straight to the content

UCB - The next generation biopharma leader

close Choose a text size

UCB News in 2010

New data for Vimpat® (lacosamide) C-V showed sustained efficacy for up to 5 years and improved seizure control when added to a broad range of antiepileptic drugs29-June-2010 | pdf file, 101 kb
Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Leg Syndrome18-June-2010 | pdf file, 64 kb
Neupro® (rotigotine transdermal system) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson's disease17-June-2010 | pdf file, 61 kb
New study showed the impact of gastointestinal disorders in patients with Parkinson's disease15-June-2010 | pdf file, 39 kb
New Oral Solution Formulation of Antiepileptic Drug Vimpat® (lacosamide) (C-V)14-June-2010 | pdf file, 72 kb
Improved Management of Severe Epilepsy May Reduce Treatment Costs19-May-2010 | PDF file, 52 kb
New data presented at the American Academy of Neurology meeting showed that Neupro® (Rotigotine Transdermal System) improved both motor and non-motor symptoms of Parkinson's disease14-April -2010 | pdf file, 71 kb
New data show sustained 5-year benefit of Neupro® (Rotigotine Transdermal System) for symptoms of Restless Leg Syndrome13-April-2010 | pdf file, 72 kb
Extensive Neupro® (Rotigotine Transdermal System) data to be presented at the 62nd American Academy of Neurology Meeting in Toronto, Canada8-April-2010 | pdf file, 62 kb
Research Supporting the Role of Antiepileptic Drug Vimpat® (lacosamide) (C-v) to be Highlighted at Upcoming AAN Meeting8-April-2010 | pdf file, 78 kb
Newly-published Study Reinforces Role of Antiepileptic Drug Vimpat® (lacosamide) (C-V) as an Add-on Treatment that Significantly Reduces Partial-onset Seizures in Adults with Epilepsy11-March-2010 | PDF file, 57 kb
UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S.29-January-2010 | pdf file, 78 kb
UCB Commemorates Epilepsy Awareness Month with New and Enhanced Patient-Centered Initiatives02-November-2009 | pdf file, 96 kb
FDA approves Xyzal® for use in children age six months and older for the relief of perennial allergic rhinitis and chronic idiopathic urticaria24-August-2009 |pdf file, 53 kb
UCB and Crohn’s disease working group award $175,000 in research grants to gastroenterology fellows01-June-2009 |pdf file, 62 kb
CIMZIA®(certolizumab pegol) provides long-term remission and response rates in Infliximab-refractory Crohn’s patients31-May-2009 |pdf file, 153 kb
UCB launches Vimpat® in the U.S. for add-on treatment of epilepsy in adults26-May-2009 |pdf file, 106 kb
Partnership unites UCB with consumer product innovator OXO®14-May-2009 |pdf file, 113 kb
UCB's CIMZIA® (certolizumab pegol) approved by the U.S. FDA for adult patients suffering from moderate to severe rheumatoid arthritis14-May-2009 |pdf file, 87 kb
UCB: Full Year 2008 Financial Results03-March-2009 |pdf file, 82 kb
UCB’s meeting with U.S. FDA defines path for Cimzia® (certolizumab pegol) in rheumatoid arthritis.06-February-2009 |pdf file, 55 kb
UCB receives Complete Response Letter from U.S. FDA for use of Cimzia® (certolizumab pegol) in rheumatoid arthritis patients.05-January-2009 |pdf file, 36 kb